At present, it has been reported that TNF-α antagonism is most likely not beneficial in the treatment of acute myocardial infarction because it decreases systemic inflammation while increasing platelet activation, which does not affect peripheral vasomotor or fibrinolytic function [27]. The gene discussed is TNF; the disease is myocardial infarction.